<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00551031</url>
  </required_header>
  <id_info>
    <org_study_id>FID29</org_study_id>
    <nct_id>NCT00551031</nct_id>
  </id_info>
  <brief_title>Study of Inactivated, Split-Virion Influenza Vaccine and Standard Fluzone® Vaccine in Adult and Elderly Subjects</brief_title>
  <official_title>Immunogenicity and Safety of Two Dosages of the Split, Inactivated, Trivalent Influenza Vaccine Administered by Intradermal Route in the Elderly Compared With Standard Fluzone® in Adults and Elderly Subjects.</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Sanofi</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Sanofi</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The present formulations are being developed for further study in the elderly population in
      order to generate additional supporting data.

      Primary Objective:

      To demonstrate non-inferiority of post-vaccination immunogenicity of subjects who received
      either 1 of the 2 investigational formulations of a trivalent inactivated vaccine (TIV)
      compared to that of the standard Fluzone® in elderly subjects.

      Secondary Objectives:

      Immunogenicity To describe the immunogenicity in subjects receiving investigational Fluzone
      and standard Fluzone®.

      Safety:

      To evaluate and describe the safety profile of investigational Fluzone in terms of solicited-
      and unsolicited adverse events and serious adverse events post-vaccination.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>October 2007</start_date>
  <completion_date type="Actual">November 2008</completion_date>
  <primary_completion_date type="Actual">June 2008</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Prevention</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Geometric Mean Titers (GMTs) Before and After Vaccination With Fluzone Intradermal or Fluzone High Dose or Fluzone Intramuscular Vaccine.</measure>
    <time_frame>Day 0 and Day 28 post vaccination</time_frame>
    <description>Serum antibody titers for the Influenza vaccine serogroups A/H1N1, A/H3N2, and B were assessed by hemagglutinin inhibition (HAI) assay.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Percentage of Participants Who Achieved Seroconversion Post-Vaccination With Fluzone Intradermal or Fluzone High Dose or Fluzone Intramuscular Vaccine</measure>
    <time_frame>Day 28 post-vaccination</time_frame>
    <description>Seroconversion defined as either a pre-vaccination hemagglutination inhibition (HAI) titer &lt; 1:10 and a post vaccination titer ≥ 1:40, or a pre-vaccination titer ≥ 1:10 and a minimum four fold increase at one month post-vaccination.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Percentage of Participants Who Achieved Seroprotection Before and Post-vaccination With Fluzone Intradermal or Fluzone High Dose or Fluzone Intramuscular Vaccine.</measure>
    <time_frame>Day 0 and Day 28 post-vaccination</time_frame>
    <description>Seroprotection was defined as a Hemagglutination inhibition (HAI) titer ≥ 1:40</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Number of Participants Reporting Solicited Injection Site or Systemic Reactions Post-vaccination With Either Fluzone Intradermal or Fluzone High Dose or Fluzone Intramuscular Vaccine.</measure>
    <time_frame>Days 0 through 7 post-vaccination</time_frame>
    <description>Solicited injection site reactions: Pain, Pruritus, Erythema, Swelling, Induration, and Ecchymosis.
Solicited systemic reactions: Fever (Temperature), Headache, Malaise, Myalgia, and Chills</description>
  </secondary_outcome>
  <number_of_arms>5</number_of_arms>
  <enrollment type="Actual">2098</enrollment>
  <condition>Influenza</condition>
  <condition>Myxovirus Infection</condition>
  <arm_group>
    <arm_group_label>Influenza Virus Vaccine Formulation 1</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Influenza Virus Vaccine Formulation 1</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Influenza Virus Vaccine Formulation 2</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Influenza Virus Vaccine Formulation 2</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Fluzone® Elderly Group</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Fluzone® High-dose Group</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Participants enrolled at age ≥ 65 years</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Fluzone® Adults Group</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Participants enrolled at age 18-49 years.</description>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>Split, Inactivated, Trivalent Influenza Vaccine (Intradermal Formulation 1)</intervention_name>
    <description>0.1 mL, Intradermal (ID)</description>
    <arm_group_label>Influenza Virus Vaccine Formulation 1</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>Split, Inactivated, Trivalent Influenza Vaccine (Intradermal Formulation 2)</intervention_name>
    <description>0.1 mL, Intradermal (ID)</description>
    <arm_group_label>Influenza Virus Vaccine Formulation 2</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>Split, Inactivated, Trivalent Influenza Vaccine (Standard dose)</intervention_name>
    <description>0.5 mL, Intramuscular (IM)</description>
    <arm_group_label>Fluzone® Elderly Group</arm_group_label>
    <other_name>Fluzone®</other_name>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>Split, Inactivated, Trivalent Influenza Vaccine (High-dose)</intervention_name>
    <description>0.5 mL, Intramuscular (IM)</description>
    <arm_group_label>Fluzone® High-dose Group</arm_group_label>
    <other_name>Fluzone® High-dose</other_name>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>Split, Inactivated, Trivalent Influenza Vaccine (Standard dose)</intervention_name>
    <description>0.5 mL, Intramuscular (IM)</description>
    <arm_group_label>Fluzone® Adults Group</arm_group_label>
    <other_name>Fluzone®</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Aged ≥ 65 years or aged 18 to 49 years on the day of vaccination.

          -  Informed consent form signed.

          -  Medically stable (Subjects may have underlying illnesses such as hypertension,
             diabetes, ischemic heart disease or hypothyroidism, as long as their symptoms/signs
             are controlled. If they are on medication for a condition, the medication dose must
             have been stable for at least 3 weeks preceding vaccination.

          -  Able to attend all scheduled visits and to comply with all trial procedures.

          -  For a woman of child-bearing potential, avoid becoming pregnant (use of an effective
             method of contraception or abstinence) for at least 4 weeks prior to vaccination,
             until at least 4 weeks after vaccination

        Exclusion Criteria:

          -  Known systemic hypersensitivity to any of the vaccine components or history of a
             life-threatening reaction to the standard-dose Fluzone® vaccine or to a vaccine
             containing any of the same substances.

          -  Known or suspected congenital or acquired immunodeficiency, hepatitis B (HBsAg) or
             hepatitis C infection or seropositivity immunosuppressive therapy such as anti-cancer
             chemotherapy or radiation therapy within the preceding 6 months, or long-term systemic
             corticosteroids therapy

          -  For a woman of child-bearing potential, known pregnancy or positive urine pregnancy
             test.

          -  Breast feeding woman.

          -  Neoplastic disease or any hematologic malignancy, (except localized skin or prostate
             cancer that is stable at the time of vaccination in the absence of therapy, as well as
             subjects who have a history of neoplastic disease and who have been disease free for ≥
             5 years).

          -  Current use of alcohol or recreational drugs that in the opinion of the Investigator
             may interfere with the subject's ability to comply with trial procedures.

          -  Receipt of blood or blood-derived products in the past 3 months that might interfere
             with the assessment of immune response.

          -  Vaccination against influenza in the past 6 months.

          -  Any vaccination in the 4 weeks preceding the trial vaccination.

          -  Planned receipt of any other vaccine in the four weeks following the trial
             vaccination.

          -  Participation in another clinical trial investigating a vaccine, drug, medical device,
             or a medical procedure in the 4 weeks preceding trial vaccination.

          -  Planned participation in another clinical trial during the present trial period.

        Note: Concomitant participation in an observational trial (not involving drugs, vaccines,
        or medical devices) is acceptable.

          -  Known thrombocytopenia or bleeding disorder or anticoagulants in the 3 weeks preceding
             inclusion contraindicating intramuscular vaccination.

          -  Chronic illness at a stage that could interfere with trial conduct or completion, in
             the opinion of the investigator

          -  Personal or family history of Guillain-Barré Syndrome.

          -  Known current human immunodeficiency virus (HIV), hepatitis B (HBsAg) or hepatitis C
             infection or seropositivity.

          -  Subject deprived of freedom by an administrative or court order, or in an emergency
             setting, or hospitalized without his/her consent.

          -  An acute febrile illness [oral temperature ≥ 99.5°F (≥ 37.5°C)] within 24 hours prior
             to vaccination. If this exists, vaccination will be deferred until the participant
             becomes afebrile.

          -  Signs and symptoms of an acute infectious respiratory illness. If this exists,
             vaccination will be deferred until the symptoms resolve.

          -  The use of an antibiotics therapy within 72 hours preceding the trial vaccination. If
             this exists, vaccination will be deferred until at least 72 hours after the last
             antibiotics therapy.

          -  Receipt of any allergy shots in the 7-day period prior to enrollment (vaccination), or
             scheduled to receive any allergy shots in the 7-day period after enrollment
             (vaccination). Subjects should be enrolled in the trial only if their allergy shots
             are given on a stable schedule outside the 7-day periods pre- and post-vaccination.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Medical Director</last_name>
    <role>Study Director</role>
    <affiliation>Sanofi Pasteur Inc.</affiliation>
  </overall_official>
  <location>
    <facility>
      <address>
        <city>Alabaster</city>
        <state>Alabama</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Mobile</city>
        <state>Alabama</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Chandler</city>
        <state>Arizona</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Mesa</city>
        <state>Arizona</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Phoenix</city>
        <state>Arizona</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Tucson</city>
        <state>Arizona</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Fountain Valley</city>
        <state>California</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>San Diego</city>
        <state>California</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Stanford</city>
        <state>Connecticut</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Pembroke Pines</city>
        <state>Florida</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Pinellas Park</city>
        <state>Florida</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Boise</city>
        <state>Idaho</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Chicago</city>
        <state>Illinois</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Wichita</city>
        <state>Kansas</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Kansas City</city>
        <state>Missouri</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Springfield</city>
        <state>Missouri</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>St. Louis</city>
        <state>Missouri</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Cary</city>
        <state>North Carolina</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Raleigh</city>
        <state>North Carolina</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Cincinnati</city>
        <state>Ohio</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Allentown</city>
        <state>Pennsylvania</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Bensalem</city>
        <state>Pennsylvania</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Warwick</city>
        <state>Rhode Island</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Goose Creek</city>
        <state>South Carolina</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Fort Worth</city>
        <state>Texas</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Galveston</city>
        <state>Texas</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Salt Lake City</city>
        <state>Utah</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>West Jordan</city>
        <state>Utah</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Marshfield</city>
        <state>Wisconsin</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <link>
    <url>http://www.sanofipasteur.com</url>
  </link>
  <link>
    <url>http://www.sanofiaventis.com</url>
  </link>
  <verification_date>April 2016</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>October 29, 2007</study_first_submitted>
  <study_first_submitted_qc>October 29, 2007</study_first_submitted_qc>
  <study_first_posted type="Estimate">October 30, 2007</study_first_posted>
  <results_first_submitted>October 13, 2011</results_first_submitted>
  <results_first_submitted_qc>October 13, 2011</results_first_submitted_qc>
  <results_first_posted type="Estimate">November 24, 2011</results_first_posted>
  <disposition_first_submitted>March 31, 2010</disposition_first_submitted>
  <disposition_first_submitted_qc>March 31, 2010</disposition_first_submitted_qc>
  <disposition_first_posted type="Estimate">April 2, 2010</disposition_first_posted>
  <last_update_submitted>April 12, 2016</last_update_submitted>
  <last_update_submitted_qc>April 12, 2016</last_update_submitted_qc>
  <last_update_posted type="Estimate">May 16, 2016</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Influenza</keyword>
  <keyword>Orthomyxoviruses</keyword>
  <keyword>Myxovirus Infection</keyword>
  <keyword>Inactivated Split-virion influenza vaccine</keyword>
  <keyword>Elderly</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Influenza, Human</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Vaccines</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <recruitment_details>Participants were enrolled from 24 October to 31 October 2007 in 31 medical centers in the US.</recruitment_details>
      <pre_assignment_details>A total of 2095 of the 2098 enrolled participants who met the inclusion and exclusion criteria were vaccinated.</pre_assignment_details>
      <group_list>
        <group group_id="P1">
          <title>Influenza Virus Vaccine Formulation 1</title>
          <description>Participants aged 65 years or older who received 1 dose of Fluzone 15 µg intradermally (ID) using the Becton Dickenson Micro Injection System</description>
        </group>
        <group group_id="P2">
          <title>Influenza Virus Vaccine Formulation 2</title>
          <description>Participants aged 65 years or older who received 1 dose of Fluzone 21 µg intradermally (ID) using the Becton Dickenson Micro Injection System</description>
        </group>
        <group group_id="P3">
          <title>Fluzone® Elderly Group</title>
          <description>Participants aged 65 years or older who received 1 dose of Fluzone 15 µg intramuscularly (IM)</description>
        </group>
        <group group_id="P4">
          <title>Fluzone® High Dose Group</title>
          <description>Participants aged 65 years or older who received 1 dose of Fluzone 60 µg intramuscularly (IM)</description>
        </group>
        <group group_id="P5">
          <title>Fluzone® Adults Group</title>
          <description>Participants aged 18 to 49 years who received 1 dose of Fluzone 15 µg intramuscularly (IM)</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="637"/>
                <participants group_id="P2" count="636"/>
                <participants group_id="P3" count="319"/>
                <participants group_id="P4" count="320"/>
                <participants group_id="P5" count="186"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="635"/>
                <participants group_id="P2" count="625"/>
                <participants group_id="P3" count="317"/>
                <participants group_id="P4" count="317"/>
                <participants group_id="P5" count="185"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="2"/>
                <participants group_id="P2" count="11"/>
                <participants group_id="P3" count="2"/>
                <participants group_id="P4" count="3"/>
                <participants group_id="P5" count="1"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Adverse Event</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="1"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Protocol Violation</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="1"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Lost to Follow-up</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="1"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="1"/>
                <participants group_id="P5" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Withdrawal by Subject</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="4"/>
                <participants group_id="P3" count="1"/>
                <participants group_id="P4" count="2"/>
                <participants group_id="P5" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Serious Adverse Event</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="2"/>
                <participants group_id="P3" count="1"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Did not receive vaccine</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="2"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Influenza Virus Vaccine Formulation 1</title>
          <description>Participants aged 65 years or older who received 1 dose of Fluzone 15 µg intradermally (ID) using the Becton Dickenson Micro Injection System</description>
        </group>
        <group group_id="B2">
          <title>Influenza Virus Vaccine Formulation 2</title>
          <description>Participants aged 65 years or older who received 1 dose of Fluzone 21 µg intradermally (ID) using the Becton Dickenson Micro Injection System</description>
        </group>
        <group group_id="B3">
          <title>Fluzone® Elderly Group</title>
          <description>Participants aged 65 years or older who received 1 dose of Fluzone 15 µg intramuscularly (IM)</description>
        </group>
        <group group_id="B4">
          <title>Fluzone® High Dose Group</title>
          <description>Participants aged 65 years or older who received 1 dose of Fluzone 60 µg intramuscularly (IM)</description>
        </group>
        <group group_id="B5">
          <title>Fluzone® Adults Group</title>
          <description>Participants aged 18 to 49 years who received 1 dose of Fluzone 15 µg intramuscularly (IM)</description>
        </group>
        <group group_id="B6">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="635"/>
            <count group_id="B2" value="635"/>
            <count group_id="B3" value="319"/>
            <count group_id="B4" value="320"/>
            <count group_id="B5" value="186"/>
            <count group_id="B6" value="2095"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>&lt;=18 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                    <measurement group_id="B5" value="0"/>
                    <measurement group_id="B6" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Between 18 and 65 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                    <measurement group_id="B5" value="186"/>
                    <measurement group_id="B6" value="186"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>&gt;=65 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="635"/>
                    <measurement group_id="B2" value="635"/>
                    <measurement group_id="B3" value="319"/>
                    <measurement group_id="B4" value="320"/>
                    <measurement group_id="B5" value="0"/>
                    <measurement group_id="B6" value="1909"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Age</title>
          <units>Years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="73.1" spread="6.03"/>
                    <measurement group_id="B2" value="72.9" spread="5.86"/>
                    <measurement group_id="B3" value="73.4" spread="5.91"/>
                    <measurement group_id="B4" value="73.0" spread="6.00"/>
                    <measurement group_id="B5" value="32.2" spread="8.49"/>
                    <measurement group_id="B6" value="64.8" spread="6.458"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Gender</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Female</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="363"/>
                    <measurement group_id="B2" value="347"/>
                    <measurement group_id="B3" value="176"/>
                    <measurement group_id="B4" value="183"/>
                    <measurement group_id="B5" value="121"/>
                    <measurement group_id="B6" value="1190"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Male</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="272"/>
                    <measurement group_id="B2" value="288"/>
                    <measurement group_id="B3" value="143"/>
                    <measurement group_id="B4" value="137"/>
                    <measurement group_id="B5" value="65"/>
                    <measurement group_id="B6" value="905"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>Participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>United States</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="635"/>
                    <measurement group_id="B2" value="635"/>
                    <measurement group_id="B3" value="319"/>
                    <measurement group_id="B4" value="320"/>
                    <measurement group_id="B5" value="186"/>
                    <measurement group_id="B6" value="2095"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Geometric Mean Titers (GMTs) Before and After Vaccination With Fluzone Intradermal or Fluzone High Dose or Fluzone Intramuscular Vaccine.</title>
        <description>Serum antibody titers for the Influenza vaccine serogroups A/H1N1, A/H3N2, and B were assessed by hemagglutinin inhibition (HAI) assay.</description>
        <time_frame>Day 0 and Day 28 post vaccination</time_frame>
        <population>Serum antibody titers GMTs were assessed in the per-protocol population.</population>
        <group_list>
          <group group_id="O1">
            <title>Influenza Virus Vaccine Formulation 1</title>
            <description>Participants aged 65 years or older who received 1 dose of Fluzone 15 µg intradermally (ID) using the Becton Dickenson Micro Injection System</description>
          </group>
          <group group_id="O2">
            <title>Influenza Virus Vaccine Formulation 2</title>
            <description>Participants aged 65 years or older who received 1 dose of Fluzone 21 µg intradermally (ID) using the Becton Dickenson Micro Injection System</description>
          </group>
          <group group_id="O3">
            <title>Fluzone® Elderly Group</title>
            <description>Participants aged 65 years or older who received 1 dose of Fluzone 15 µg intramuscularly (IM)</description>
          </group>
          <group group_id="O4">
            <title>Fluzone® High Dose Group</title>
            <description>Participants aged 65 years or older who received 1 dose of Fluzone 60 µg intramuscularly (IM)</description>
          </group>
          <group group_id="O5">
            <title>Fluzone® Adults Group</title>
            <description>Participants aged 18 to 49 years who received 1 dose of Fluzone 15 µg intramuscularly (IM)</description>
          </group>
        </group_list>
        <measure>
          <title>Geometric Mean Titers (GMTs) Before and After Vaccination With Fluzone Intradermal or Fluzone High Dose or Fluzone Intramuscular Vaccine.</title>
          <description>Serum antibody titers for the Influenza vaccine serogroups A/H1N1, A/H3N2, and B were assessed by hemagglutinin inhibition (HAI) assay.</description>
          <population>Serum antibody titers GMTs were assessed in the per-protocol population.</population>
          <units>Titers</units>
          <param>Geometric Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="607"/>
                <count group_id="O2" value="608"/>
                <count group_id="O3" value="304"/>
                <count group_id="O4" value="309"/>
                <count group_id="O5" value="179"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>A/H1N1 Pre Dose (N=604, 607, 304, 309, 179)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="18.3" lower_limit="16.9" upper_limit="19.8"/>
                    <measurement group_id="O2" value="18.6" lower_limit="17.1" upper_limit="20.2"/>
                    <measurement group_id="O3" value="17.8" lower_limit="15.7" upper_limit="20.0"/>
                    <measurement group_id="O4" value="17.3" lower_limit="15.3" upper_limit="19.5"/>
                    <measurement group_id="O5" value="41.4" lower_limit="32.6" upper_limit="52.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>A/H1N1 Post Dose (N=605, 607, 304, 309, 179)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="165.4" lower_limit="149.2" upper_limit="183.4"/>
                    <measurement group_id="O2" value="174.1" lower_limit="157.5" upper_limit="192.4"/>
                    <measurement group_id="O3" value="107.6" lower_limit="93.2" upper_limit="124.3"/>
                    <measurement group_id="O4" value="236.1" lower_limit="207.3" upper_limit="268.9"/>
                    <measurement group_id="O5" value="345.8" lower_limit="294.1" upper_limit="406.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>A/H3N2 Pre Dose (N=606, 608, 304, 309, 179)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="103.8" lower_limit="93.1" upper_limit="115.9"/>
                    <measurement group_id="O2" value="104.7" lower_limit="93.9" upper_limit="116.7"/>
                    <measurement group_id="O3" value="95.1" lower_limit="82.1" upper_limit="110.3"/>
                    <measurement group_id="O4" value="99.3" lower_limit="84.6" upper_limit="116.7"/>
                    <measurement group_id="O5" value="73.0" lower_limit="58.7" upper_limit="90.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>A/H3N2 Post Dose (N=605, 608, 304, 309, 179)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="348.3" lower_limit="320.2" upper_limit="378.9"/>
                    <measurement group_id="O2" value="378.4" lower_limit="346.9" upper_limit="412.7"/>
                    <measurement group_id="O3" value="276.9" lower_limit="245.8" upper_limit="311.8"/>
                    <measurement group_id="O4" value="508.0" lower_limit="452.6" upper_limit="570.1"/>
                    <measurement group_id="O5" value="398.3" lower_limit="343.4" upper_limit="461.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>B Pre Dose (N=607, 608, 304, 309, 179)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="24.7" lower_limit="22.9" upper_limit="26.6"/>
                    <measurement group_id="O2" value="25.1" lower_limit="23.3" upper_limit="27.1"/>
                    <measurement group_id="O3" value="24.7" lower_limit="22.2" upper_limit="27.4"/>
                    <measurement group_id="O4" value="24.1" lower_limit="21.7" upper_limit="26.8"/>
                    <measurement group_id="O5" value="15.5" lower_limit="13.4" upper_limit="17.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>B Post Dose (N=607, 608, 304, 309, 179)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="45.3" lower_limit="42.3" upper_limit="48.4"/>
                    <measurement group_id="O2" value="47.5" lower_limit="44.3" upper_limit="50.9"/>
                    <measurement group_id="O3" value="43.4" lower_limit="39.2" upper_limit="48.0"/>
                    <measurement group_id="O4" value="59.9" lower_limit="54.5" upper_limit="65.9"/>
                    <measurement group_id="O5" value="71.2" lower_limit="61.7" upper_limit="82.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Percentage of Participants Who Achieved Seroconversion Post-Vaccination With Fluzone Intradermal or Fluzone High Dose or Fluzone Intramuscular Vaccine</title>
        <description>Seroconversion defined as either a pre-vaccination hemagglutination inhibition (HAI) titer &lt; 1:10 and a post vaccination titer ≥ 1:40, or a pre-vaccination titer ≥ 1:10 and a minimum four fold increase at one month post-vaccination.</description>
        <time_frame>Day 28 post-vaccination</time_frame>
        <population>Serum antibody titers were assessed in the per protocol population.</population>
        <group_list>
          <group group_id="O1">
            <title>Influenza Virus Vaccine Formulation 1</title>
            <description>Participants aged 65 years or older who received 1 dose of Fluzone 15 µg intradermally (ID) using the Becton Dickenson Micro Injection System</description>
          </group>
          <group group_id="O2">
            <title>Influenza Virus Vaccine Formulation 2</title>
            <description>Participants aged 65 years or older who received 1 dose of Fluzone 21 µg intradermally (ID) using the Becton Dickenson Micro Injection System</description>
          </group>
          <group group_id="O3">
            <title>Fluzone® Elderly Group</title>
            <description>Participants aged 65 years or older who received 1 dose of Fluzone 15 µg intramuscularly (IM)</description>
          </group>
          <group group_id="O4">
            <title>Fluzone® High Dose Group</title>
            <description>Participants aged 65 years or older who received 1 dose of Fluzone 60 µg intramuscularly (IM)</description>
          </group>
          <group group_id="O5">
            <title>Fluzone® Adults Group</title>
            <description>Participants aged 18 to 49 years who received 1 dose of Fluzone 15 µg intramuscularly (IM)</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Participants Who Achieved Seroconversion Post-Vaccination With Fluzone Intradermal or Fluzone High Dose or Fluzone Intramuscular Vaccine</title>
          <description>Seroconversion defined as either a pre-vaccination hemagglutination inhibition (HAI) titer &lt; 1:10 and a post vaccination titer ≥ 1:40, or a pre-vaccination titer ≥ 1:10 and a minimum four fold increase at one month post-vaccination.</description>
          <population>Serum antibody titers were assessed in the per protocol population.</population>
          <units>Percentage of Participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="607"/>
                <count group_id="O2" value="608"/>
                <count group_id="O3" value="304"/>
                <count group_id="O4" value="309"/>
                <count group_id="O5" value="179"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>A/H1N1 (N=604, 607, 304, 309, 179)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="73"/>
                    <measurement group_id="O2" value="74"/>
                    <measurement group_id="O3" value="61" lower_limit="0" upper_limit="0"/>
                    <measurement group_id="O4" value="82"/>
                    <measurement group_id="O5" value="62"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>A/H3N2 (N=605, 608, 304, 309, 179)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="42"/>
                    <measurement group_id="O2" value="42"/>
                    <measurement group_id="O3" value="37" lower_limit="0" upper_limit="0"/>
                    <measurement group_id="O4" value="56"/>
                    <measurement group_id="O5" value="52"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>B (N=607, 608, 304, 309, 179)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="15"/>
                    <measurement group_id="O2" value="15"/>
                    <measurement group_id="O3" value="9" lower_limit="0" upper_limit="0"/>
                    <measurement group_id="O4" value="26"/>
                    <measurement group_id="O5" value="44"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Percentage of Participants Who Achieved Seroprotection Before and Post-vaccination With Fluzone Intradermal or Fluzone High Dose or Fluzone Intramuscular Vaccine.</title>
        <description>Seroprotection was defined as a Hemagglutination inhibition (HAI) titer ≥ 1:40</description>
        <time_frame>Day 0 and Day 28 post-vaccination</time_frame>
        <population>Serum antibody titers were assessed in the per protocol population.</population>
        <group_list>
          <group group_id="O1">
            <title>Influenza Virus Vaccine Formulation 1</title>
            <description>Participants aged 65 years or older who received 1 dose of Fluzone 15 µg intradermally (ID) using the Becton Dickenson Micro Injection System</description>
          </group>
          <group group_id="O2">
            <title>Influenza Virus Vaccine Formulation 2</title>
            <description>Participants aged 65 years or older who received 1 dose of Fluzone 21 µg intradermally (ID) using the Becton Dickenson Micro Injection System</description>
          </group>
          <group group_id="O3">
            <title>Fluzone® Elderly Group</title>
            <description>Participants aged 65 years or older who received 1 dose of Fluzone 15 µg intramuscularly (IM)</description>
          </group>
          <group group_id="O4">
            <title>Fluzone® High Dose Group</title>
            <description>Participants aged 65 years or older who received 1 dose of Fluzone 60 µg intramuscularly (IM)</description>
          </group>
          <group group_id="O5">
            <title>Fluzone® Adults Group</title>
            <description>Participants aged 18 to 49 years who received 1 dose of Fluzone 15 µg intramuscularly (IM)</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Participants Who Achieved Seroprotection Before and Post-vaccination With Fluzone Intradermal or Fluzone High Dose or Fluzone Intramuscular Vaccine.</title>
          <description>Seroprotection was defined as a Hemagglutination inhibition (HAI) titer ≥ 1:40</description>
          <population>Serum antibody titers were assessed in the per protocol population.</population>
          <units>Percentage of Participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="607"/>
                <count group_id="O2" value="608"/>
                <count group_id="O3" value="304"/>
                <count group_id="O4" value="309"/>
                <count group_id="O5" value="179"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>A/H1N1 Pre Dose (N=604, 607, 304, 309, 179)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="27"/>
                    <measurement group_id="O2" value="25"/>
                    <measurement group_id="O3" value="25"/>
                    <measurement group_id="O4" value="23"/>
                    <measurement group_id="O5" value="49"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>A/H1N1 Post Dose (N=605, 607, 304, 309, 179)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="88"/>
                    <measurement group_id="O2" value="90"/>
                    <measurement group_id="O3" value="79"/>
                    <measurement group_id="O4" value="94"/>
                    <measurement group_id="O5" value="97"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>A/H3N2 Pre Dose (N=606, 608, 304, 309, 179)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="78"/>
                    <measurement group_id="O2" value="79"/>
                    <measurement group_id="O3" value="80"/>
                    <measurement group_id="O4" value="78"/>
                    <measurement group_id="O5" value="72"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>A/H3N2 Post Dose (N=605, 608, 304, 309, 179)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="98"/>
                    <measurement group_id="O2" value="98"/>
                    <measurement group_id="O3" value="97"/>
                    <measurement group_id="O4" value="99"/>
                    <measurement group_id="O5" value="99"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>B Pre Dose (N=607, 608, 304, 309, 179)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="38"/>
                    <measurement group_id="O2" value="37"/>
                    <measurement group_id="O3" value="39"/>
                    <measurement group_id="O4" value="37"/>
                    <measurement group_id="O5" value="25"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>B Post Dose (N=607, 608, 304, 309, 179)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="65"/>
                    <measurement group_id="O2" value="67"/>
                    <measurement group_id="O3" value="62"/>
                    <measurement group_id="O4" value="77"/>
                    <measurement group_id="O5" value="79"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Participants Reporting Solicited Injection Site or Systemic Reactions Post-vaccination With Either Fluzone Intradermal or Fluzone High Dose or Fluzone Intramuscular Vaccine.</title>
        <description>Solicited injection site reactions: Pain, Pruritus, Erythema, Swelling, Induration, and Ecchymosis.
Solicited systemic reactions: Fever (Temperature), Headache, Malaise, Myalgia, and Chills</description>
        <time_frame>Days 0 through 7 post-vaccination</time_frame>
        <population>Safety analysis was on all enrolled and vaccinated subjects with available reaction data, intent to treat population.</population>
        <group_list>
          <group group_id="O1">
            <title>Influenza Virus Vaccine Formulation 1</title>
            <description>Participants aged 65 years or older who received 1 dose of Fluzone 15 µg intradermally (ID) using the Becton Dickenson Micro Injection System</description>
          </group>
          <group group_id="O2">
            <title>Influenza Virus Vaccine Formulation 2</title>
            <description>Participants aged 65 years or older who received 1 dose of Fluzone 21 µg intradermally (ID) using the Becton Dickenson Micro Injection System</description>
          </group>
          <group group_id="O3">
            <title>Fluzone® Elderly Group</title>
            <description>Participants aged 65 years or older who received 1 dose of Fluzone 15 µg intramuscularly (IM)</description>
          </group>
          <group group_id="O4">
            <title>Fluzone® High Dose Group</title>
            <description>Participants aged 65 years or older who received 1 dose of Fluzone 60 µg intramuscularly (IM)</description>
          </group>
          <group group_id="O5">
            <title>Fluzone® Adults Group</title>
            <description>Participants aged 18 to 49 years who received 1 dose of Fluzone 15 µg intramuscularly (IM)</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants Reporting Solicited Injection Site or Systemic Reactions Post-vaccination With Either Fluzone Intradermal or Fluzone High Dose or Fluzone Intramuscular Vaccine.</title>
          <description>Solicited injection site reactions: Pain, Pruritus, Erythema, Swelling, Induration, and Ecchymosis.
Solicited systemic reactions: Fever (Temperature), Headache, Malaise, Myalgia, and Chills</description>
          <population>Safety analysis was on all enrolled and vaccinated subjects with available reaction data, intent to treat population.</population>
          <units>Participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="635"/>
                <count group_id="O2" value="635"/>
                <count group_id="O3" value="319"/>
                <count group_id="O4" value="320"/>
                <count group_id="O5" value="186"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Any Injection Site Pain</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="174"/>
                    <measurement group_id="O2" value="187"/>
                    <measurement group_id="O3" value="57"/>
                    <measurement group_id="O4" value="117"/>
                    <measurement group_id="O5" value="106"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Grade 3 Pain (Prevents daily activities)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="0"/>
                    <measurement group_id="O5" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Any Injection Site Pruritus</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="204"/>
                    <measurement group_id="O2" value="214"/>
                    <measurement group_id="O3" value="27"/>
                    <measurement group_id="O4" value="17"/>
                    <measurement group_id="O5" value="24"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Grade 3 Pruritus (Prevents daily activities)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2"/>
                    <measurement group_id="O2" value="3"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="0"/>
                    <measurement group_id="O5" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Any Injection Site Erythema</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="426"/>
                    <measurement group_id="O2" value="434"/>
                    <measurement group_id="O3" value="48"/>
                    <measurement group_id="O4" value="55"/>
                    <measurement group_id="O5" value="29"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Grade 3 Erythema (≥ 5 cm)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="109"/>
                    <measurement group_id="O2" value="108"/>
                    <measurement group_id="O3" value="5"/>
                    <measurement group_id="O4" value="12"/>
                    <measurement group_id="O5" value="5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Any Injection Site Swelling</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="286"/>
                    <measurement group_id="O2" value="286"/>
                    <measurement group_id="O3" value="23" lower_limit="0" upper_limit="0"/>
                    <measurement group_id="O4" value="45"/>
                    <measurement group_id="O5" value="14"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Grade 3 Swelling (≥ 5 cm)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="50"/>
                    <measurement group_id="O2" value="49"/>
                    <measurement group_id="O3" value="6"/>
                    <measurement group_id="O4" value="16"/>
                    <measurement group_id="O5" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Any Injection Site Induration</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="310"/>
                    <measurement group_id="O2" value="311"/>
                    <measurement group_id="O3" value="33"/>
                    <measurement group_id="O4" value="45"/>
                    <measurement group_id="O5" value="20"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Grade 3 Induration (≥ 5 cm)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="41"/>
                    <measurement group_id="O2" value="43"/>
                    <measurement group_id="O3" value="5"/>
                    <measurement group_id="O4" value="12"/>
                    <measurement group_id="O5" value="4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Any Injection Site Ecchymosis</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="38"/>
                    <measurement group_id="O2" value="41"/>
                    <measurement group_id="O3" value="19"/>
                    <measurement group_id="O4" value="17"/>
                    <measurement group_id="O5" value="14"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Grade 3 Ecchymosis (≥ 5 cm)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="5"/>
                    <measurement group_id="O2" value="9"/>
                    <measurement group_id="O3" value="2"/>
                    <measurement group_id="O4" value="2"/>
                    <measurement group_id="O5" value="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Any Fever</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="14"/>
                    <measurement group_id="O2" value="18"/>
                    <measurement group_id="O3" value="5"/>
                    <measurement group_id="O4" value="17"/>
                    <measurement group_id="O5" value="10"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Grade 3 Fever (&gt; 102.2 ºF)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="0"/>
                    <measurement group_id="O5" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Any Headache</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="103"/>
                    <measurement group_id="O2" value="89"/>
                    <measurement group_id="O3" value="41"/>
                    <measurement group_id="O4" value="59"/>
                    <measurement group_id="O5" value="61"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Grade 3 Headache (Prevents daily activities)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2"/>
                    <measurement group_id="O2" value="6"/>
                    <measurement group_id="O3" value="1"/>
                    <measurement group_id="O4" value="2"/>
                    <measurement group_id="O5" value="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Any Malaise</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="76"/>
                    <measurement group_id="O2" value="98"/>
                    <measurement group_id="O3" value="42"/>
                    <measurement group_id="O4" value="50"/>
                    <measurement group_id="O5" value="45"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Grade 3 Malaise (Prevents daily activities)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="5"/>
                    <measurement group_id="O2" value="3"/>
                    <measurement group_id="O3" value="0" lower_limit="0" upper_limit="0"/>
                    <measurement group_id="O4" value="3"/>
                    <measurement group_id="O5" value="6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Any Myalgia</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="86"/>
                    <measurement group_id="O2" value="106"/>
                    <measurement group_id="O3" value="46"/>
                    <measurement group_id="O4" value="79"/>
                    <measurement group_id="O5" value="68"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Grade 3 Myalgia (Prevents daily activities)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2"/>
                    <measurement group_id="O2" value="2"/>
                    <measurement group_id="O3" value="1"/>
                    <measurement group_id="O4" value="3"/>
                    <measurement group_id="O5" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Any Chills</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="21"/>
                    <measurement group_id="O2" value="32"/>
                    <measurement group_id="O3" value="9"/>
                    <measurement group_id="O4" value="28"/>
                    <measurement group_id="O5" value="17"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Grade 3 Chills (Prevents daily activities)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="3"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="2"/>
                    <measurement group_id="O5" value="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>Adverse events data were collected from the day of vaccination up to 6 months post-vaccination.</time_frame>
      <group_list>
        <group group_id="E1">
          <title>Influenza Virus Vaccine Formulation 1</title>
          <description>Participants aged 65 years or older who received 1 dose of Fluzone 15 µg intradermally (ID) using the Becton Dickenson Micro Injection System</description>
        </group>
        <group group_id="E2">
          <title>Influenza Virus Vaccine Formulation 2</title>
          <description>Participants aged 65 years or older who received 1 dose of Fluzone 21 µg intradermally (ID) using the Becton Dickenson Micro Injection System</description>
        </group>
        <group group_id="E3">
          <title>Fluzone® Elderly Group</title>
          <description>Participants aged 65 years or older who received 1 dose of Fluzone 15 µg intramuscularly (IM)</description>
        </group>
        <group group_id="E4">
          <title>Fluzone® High Dose Group</title>
          <description>Participants aged 65 years or older who received 1 dose of Fluzone 60 µg intramuscularly (IM)</description>
        </group>
        <group group_id="E5">
          <title>Fluzone® Adults Group</title>
          <description>Participants aged 18 to 49 years who received 1 dose of Fluzone 15 µg intramuscularly (IM)</description>
        </group>
      </group_list>
      <serious_events>
        <default_vocab>MedDRA 10.0</default_vocab>
        <default_assessment>Non-systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="34" subjects_at_risk="635"/>
                <counts group_id="E2" subjects_affected="38" subjects_at_risk="635"/>
                <counts group_id="E3" subjects_affected="21" subjects_at_risk="319"/>
                <counts group_id="E4" subjects_affected="16" subjects_at_risk="320"/>
                <counts group_id="E5" subjects_affected="7" subjects_at_risk="186"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Blood and lymphatic system disorders</title>
            <event_list>
              <event>
                <sub_title vocab="MedDRA10.0">Microcytic anaemia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="635"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="635"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="319"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="320"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="186"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Cardiac disorders</title>
            <event_list>
              <event>
                <sub_title>Acute myocardial infarction</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="635"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="635"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="319"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="320"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="186"/>
              </event>
              <event>
                <sub_title>Angina pectoris</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="635"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="635"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="319"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="320"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="186"/>
              </event>
              <event>
                <sub_title>Atrial fibrillation</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="635"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="635"/>
                <counts group_id="E3" events="2" subjects_affected="2" subjects_at_risk="319"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="320"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="186"/>
              </event>
              <event>
                <sub_title>Cardiac arrest</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="635"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="635"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="319"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="320"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="186"/>
              </event>
              <event>
                <sub_title>Cardiac failure</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="635"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="635"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="319"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="320"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="186"/>
              </event>
              <event>
                <sub_title>Cardiac failure congestive</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="635"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="635"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="319"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="320"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="186"/>
              </event>
              <event>
                <sub_title>Cardiovascular disorder</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="635"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="635"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="319"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="320"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="186"/>
              </event>
              <event>
                <sub_title>Coronary artery disease</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="635"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="635"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="319"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="320"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="186"/>
              </event>
              <event>
                <sub_title>Ventricular tachycardia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="635"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="635"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="319"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="320"/>
                <counts group_id="E5" events="1" subjects_affected="1" subjects_at_risk="186"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Ear and labyrinth disorders</title>
            <event_list>
              <event>
                <sub_title>Meniere's disease</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="635"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="635"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="319"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="320"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="186"/>
              </event>
              <event>
                <sub_title>Vertigo</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="635"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="635"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="319"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="320"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="186"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Abdominal pain</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="635"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="635"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="319"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="320"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="186"/>
              </event>
              <event>
                <sub_title>Colitis ulcerative</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="635"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="635"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="319"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="319"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="186"/>
              </event>
              <event>
                <sub_title>Gastric ulcer</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="635"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="635"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="319"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="320"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="186"/>
              </event>
              <event>
                <sub_title>Gasgtrooesophageal reflux disease</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="635"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="635"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="319"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="320"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="186"/>
              </event>
              <event>
                <sub_title>Intestinal perforation</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="635"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="635"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="319"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="320"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="186"/>
              </event>
              <event>
                <sub_title>Large intestine perforation</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="635"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="635"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="319"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="320"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="186"/>
              </event>
              <event>
                <sub_title>Oesophagitis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="635"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="635"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="319"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="320"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="186"/>
              </event>
              <event>
                <sub_title>Pancreatitis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="635"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="635"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="319"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="320"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="186"/>
              </event>
              <event>
                <sub_title>Pancreatitis acute</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="635"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="635"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="319"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="320"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="186"/>
              </event>
              <event>
                <sub_title>Small intestinal obstruction</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="635"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="635"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="319"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="320"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="186"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Chest pain</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="635"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="635"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="319"/>
                <counts group_id="E4" events="2" subjects_affected="2" subjects_at_risk="319"/>
                <counts group_id="E5" events="1" subjects_affected="1" subjects_at_risk="186"/>
              </event>
              <event>
                <sub_title>Influenza like illness</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="635"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="635"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="319"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="320"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="186"/>
              </event>
              <event>
                <sub_title>Non cardiac chest pain</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="635"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="635"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="319"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="320"/>
                <counts group_id="E5" events="1" subjects_affected="1" subjects_at_risk="186"/>
              </event>
              <event>
                <sub_title>Pain</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="635"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="635"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="319"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="320"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="186"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Hepatobiliary disorders</title>
            <event_list>
              <event>
                <sub_title>Biliary colic</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="635"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="635"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="319"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="320"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="186"/>
              </event>
              <event>
                <sub_title>Gallbladder disorder</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="635"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="635"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="319"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="320"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="186"/>
              </event>
              <event>
                <sub_title>Hepatic failure</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="635"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="635"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="319"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="320"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="186"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Immune system disorders</title>
            <event_list>
              <event>
                <sub_title>Drug hypersensitivity</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="635"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="635"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="319"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="320"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="186"/>
              </event>
              <event>
                <sub_title>Hypersensitivity</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="635"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="635"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="319"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="320"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="186"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Bronchitis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="635"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="635"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="319"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="320"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="186"/>
              </event>
              <event>
                <sub_title>Cellulitis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="635"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="635"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="319"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="320"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="186"/>
              </event>
              <event>
                <sub_title>Clostridial infection</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="635"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="635"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="319"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="320"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="186"/>
              </event>
              <event>
                <sub_title>Diverticulitis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="635"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="635"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="319"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="320"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="186"/>
              </event>
              <event>
                <sub_title>Infection</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="635"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="635"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="319"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="320"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="186"/>
              </event>
              <event>
                <sub_title>Influenza</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="635"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="635"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="319"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="320"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="186"/>
              </event>
              <event>
                <sub_title>Otitis media</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="635"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="635"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="319"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="320"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="186"/>
              </event>
              <event>
                <sub_title>Pneumonia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="635"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="635"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="319"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="320"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="186"/>
              </event>
              <event>
                <sub_title>Viral infection</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="635"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="635"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="319"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="320"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="186"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Injury, poisoning and procedural complications</title>
            <event_list>
              <event>
                <sub_title>Cardiac pacemaker malfunction</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="635"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="635"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="319"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="320"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="186"/>
              </event>
              <event>
                <sub_title>Dislocation of joint prosthesis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="635"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="635"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="319"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="320"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="186"/>
              </event>
              <event>
                <sub_title>Head injury</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="635"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="635"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="319"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="320"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="186"/>
              </event>
              <event>
                <sub_title>Hip fracture</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="635"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="635"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="319"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="320"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="186"/>
              </event>
              <event>
                <sub_title>Humerus fracture</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="635"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="635"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="319"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="320"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="186"/>
              </event>
              <event>
                <sub_title>Joint injury</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="635"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="635"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="319"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="320"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="186"/>
              </event>
              <event>
                <sub_title>Procedural pain</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="635"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="635"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="319"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="320"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="186"/>
              </event>
              <event>
                <sub_title>Renal haematoma</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="635"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="635"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="319"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="320"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="186"/>
              </event>
              <event>
                <sub_title>Spinal compression fracture</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="635"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="635"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="319"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="320"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="186"/>
              </event>
              <event>
                <sub_title>Stent graft material failure</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="635"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="635"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="319"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="320"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="186"/>
              </event>
              <event>
                <sub_title>Subdural haematoma</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="635"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="635"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="319"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="320"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="186"/>
              </event>
              <event>
                <sub_title>International normalised ratio increased</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="635"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="635"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="319"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="320"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="186"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Metabolism and nutrition disorders</title>
            <event_list>
              <event>
                <sub_title>Dehydration</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="635"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="635"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="319"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="320"/>
                <counts group_id="E5" events="1" subjects_affected="1" subjects_at_risk="186"/>
              </event>
              <event>
                <sub_title>Hypokalaemia</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="635"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="635"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="319"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="320"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="186"/>
              </event>
              <event>
                <sub_title>Hyponatraemia</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="635"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="635"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="319"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="320"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="186"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Back pain</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="635"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="635"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="319"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="320"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="186"/>
              </event>
              <event>
                <sub_title>Intervertebral disc protrusion</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="635"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="635"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="319"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="320"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="186"/>
              </event>
              <event>
                <sub_title>Muscular weakness</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="635"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="635"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="319"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="320"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="186"/>
              </event>
              <event>
                <sub_title>Neck pain</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="635"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="635"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="319"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="320"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="186"/>
              </event>
              <event>
                <sub_title>Osteoarthritis</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="635"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="635"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="319"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="320"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="186"/>
              </event>
              <event>
                <sub_title>Rhabdomyolysis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="635"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="635"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="319"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="320"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="186"/>
              </event>
              <event>
                <sub_title>Rotator cuff syndrome</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="635"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="635"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="319"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="320"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="186"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Neoplasms benign, malignant and unspecified (incl cysts and polyps)</title>
            <event_list>
              <event>
                <sub_title>Bladder cancer</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="635"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="635"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="319"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="320"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="186"/>
              </event>
              <event>
                <sub_title>Breast cancer</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="635"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="635"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="319"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="320"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="186"/>
              </event>
              <event>
                <sub_title>Chronic lymphocytic leukaemia</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="635"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="635"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="319"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="320"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="186"/>
              </event>
              <event>
                <sub_title>Colon cancer</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="635"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="635"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="319"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="320"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="186"/>
              </event>
              <event>
                <sub_title>Lung adenocarcinoma</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="635"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="635"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="319"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="320"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="186"/>
              </event>
              <event>
                <sub_title>Lung neoplasm malignant</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="635"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="635"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="319"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="320"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="186"/>
              </event>
              <event>
                <sub_title>Pancreatic carcinoma</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="635"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="635"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="319"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="320"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="186"/>
              </event>
              <event>
                <sub_title>Prostate cancer</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="635"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="635"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="319"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="320"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="186"/>
              </event>
              <event>
                <sub_title>Prostate cancer recurrent</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="635"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="635"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="319"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="320"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="186"/>
              </event>
              <event>
                <sub_title>Small cell lung cancer metastatic</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="635"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="635"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="319"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="320"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="186"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Carotid artery stenosis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="635"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="635"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="319"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="320"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="186"/>
              </event>
              <event>
                <sub_title>Cerebrovascular accident</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="635"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="635"/>
                <counts group_id="E3" events="3" subjects_affected="3" subjects_at_risk="319"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="320"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="186"/>
              </event>
              <event>
                <sub_title>Intracranial aneurysm</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="635"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="635"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="319"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="320"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="186"/>
              </event>
              <event>
                <sub_title>Lumbar radiculopathy</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="635"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="635"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="319"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="320"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="186"/>
              </event>
              <event>
                <sub_title>Presyncope</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="635"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="635"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="319"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="320"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="186"/>
              </event>
              <event>
                <sub_title>Syncope</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="635"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="635"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="319"/>
                <counts group_id="E4" events="2" subjects_affected="2" subjects_at_risk="320"/>
                <counts group_id="E5" events="1" subjects_affected="1" subjects_at_risk="186"/>
              </event>
              <event>
                <sub_title>Thrombotic stroke</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="635"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="635"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="319"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="320"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="186"/>
              </event>
              <event>
                <sub_title>Transient ischaemic attack</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="635"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="635"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="319"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="320"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="186"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Psychiatric disorders</title>
            <event_list>
              <event>
                <sub_title>Depression</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="635"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="635"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="319"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="320"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="186"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Renal and urinary disorders</title>
            <event_list>
              <event>
                <sub_title>Bladder prolapse</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="635"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="635"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="319"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="320"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="186"/>
              </event>
              <event>
                <sub_title>Renal failure acute</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="635"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="635"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="319"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="320"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="186"/>
              </event>
              <event>
                <sub_title>Urinary incontinence</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="635"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="635"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="319"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="320"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="186"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Asthma</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="635"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="635"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="319"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="320"/>
                <counts group_id="E5" events="1" subjects_affected="1" subjects_at_risk="186"/>
              </event>
              <event>
                <sub_title>Chronic obstructive pulmonary disease</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="635"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="635"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="319"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="320"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="186"/>
              </event>
              <event>
                <sub_title>Hypoxia</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="635"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="635"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="319"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="320"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="186"/>
              </event>
              <event>
                <sub_title>Pharyngeal mass</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="635"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="635"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="319"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="320"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="186"/>
              </event>
              <event>
                <sub_title>Respiratory failure</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="635"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="635"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="319"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="320"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="186"/>
              </event>
              <event>
                <sub_title>Status asthmaticus</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="635"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="635"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="319"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="320"/>
                <counts group_id="E5" events="1" subjects_affected="1" subjects_at_risk="186"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Vascular disorders</title>
            <event_list>
              <event>
                <sub_title>Arteriosclerosis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="635"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="635"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="319"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="320"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="186"/>
              </event>
              <event>
                <sub_title>Peripheral vascular disorder</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="635"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="635"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="319"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="320"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="186"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>5.00</frequency_threshold>
        <default_vocab>MedDRA 10.0</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="426" subjects_at_risk="635"/>
                <counts group_id="E2" subjects_affected="434" subjects_at_risk="635"/>
                <counts group_id="E3" subjects_affected="57" subjects_at_risk="319"/>
                <counts group_id="E4" subjects_affected="117" subjects_at_risk="320"/>
                <counts group_id="E5" subjects_affected="106" subjects_at_risk="186"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Injection site pain</sub_title>
                <counts group_id="E1" events="174" subjects_affected="174" subjects_at_risk="635"/>
                <counts group_id="E2" events="187" subjects_affected="187" subjects_at_risk="632"/>
                <counts group_id="E3" events="57" subjects_affected="57" subjects_at_risk="319"/>
                <counts group_id="E4" events="117" subjects_affected="117" subjects_at_risk="318"/>
                <counts group_id="E5" events="106" subjects_affected="106" subjects_at_risk="185"/>
              </event>
              <event>
                <sub_title>Injection site pruritus</sub_title>
                <counts group_id="E1" events="204" subjects_affected="204" subjects_at_risk="635"/>
                <counts group_id="E2" events="214" subjects_affected="214" subjects_at_risk="632"/>
                <counts group_id="E3" events="27" subjects_affected="27" subjects_at_risk="319"/>
                <counts group_id="E4" events="17" subjects_affected="17" subjects_at_risk="318"/>
                <counts group_id="E5" events="24" subjects_affected="24" subjects_at_risk="185"/>
              </event>
              <event>
                <sub_title>Injection site erythema</sub_title>
                <counts group_id="E1" events="426" subjects_affected="426" subjects_at_risk="635"/>
                <counts group_id="E2" events="434" subjects_affected="434" subjects_at_risk="632"/>
                <counts group_id="E3" events="48" subjects_affected="48" subjects_at_risk="319"/>
                <counts group_id="E4" events="55" subjects_affected="55" subjects_at_risk="319"/>
                <counts group_id="E5" events="29" subjects_affected="29" subjects_at_risk="185"/>
              </event>
              <event>
                <sub_title>Injection site swelling</sub_title>
                <counts group_id="E1" events="286" subjects_affected="286" subjects_at_risk="635"/>
                <counts group_id="E2" events="286" subjects_affected="286" subjects_at_risk="631"/>
                <counts group_id="E3" events="23" subjects_affected="23" subjects_at_risk="319"/>
                <counts group_id="E4" events="45" subjects_affected="45" subjects_at_risk="319"/>
                <counts group_id="E5" events="14" subjects_affected="14" subjects_at_risk="185"/>
              </event>
              <event>
                <sub_title>Injection site induration</sub_title>
                <counts group_id="E1" events="310" subjects_affected="310" subjects_at_risk="635"/>
                <counts group_id="E2" events="311" subjects_affected="311" subjects_at_risk="631"/>
                <counts group_id="E3" events="33" subjects_affected="33" subjects_at_risk="319"/>
                <counts group_id="E4" events="45" subjects_affected="45" subjects_at_risk="319"/>
                <counts group_id="E5" events="20" subjects_affected="20" subjects_at_risk="185"/>
              </event>
              <event>
                <sub_title>Injection site ecchymosis</sub_title>
                <counts group_id="E1" events="38" subjects_affected="38" subjects_at_risk="634"/>
                <counts group_id="E2" events="41" subjects_affected="41" subjects_at_risk="631"/>
                <counts group_id="E3" events="19" subjects_affected="19" subjects_at_risk="319"/>
                <counts group_id="E4" events="17" subjects_affected="17" subjects_at_risk="319"/>
                <counts group_id="E5" events="14" subjects_affected="14" subjects_at_risk="185"/>
              </event>
              <event>
                <sub_title>Fever</sub_title>
                <counts group_id="E1" events="14" subjects_affected="14" subjects_at_risk="630"/>
                <counts group_id="E2" events="18" subjects_affected="18" subjects_at_risk="630"/>
                <counts group_id="E3" events="5" subjects_affected="5" subjects_at_risk="319"/>
                <counts group_id="E4" events="17" subjects_affected="17" subjects_at_risk="318"/>
                <counts group_id="E5" events="10" subjects_affected="10" subjects_at_risk="182"/>
              </event>
              <event>
                <sub_title>Malaise</sub_title>
                <counts group_id="E1" events="76" subjects_affected="76" subjects_at_risk="634"/>
                <counts group_id="E2" events="98" subjects_affected="98" subjects_at_risk="631"/>
                <counts group_id="E3" events="42" subjects_affected="42" subjects_at_risk="319"/>
                <counts group_id="E4" events="50" subjects_affected="50" subjects_at_risk="319"/>
                <counts group_id="E5" events="45" subjects_affected="45" subjects_at_risk="185"/>
              </event>
              <event>
                <sub_title>Chills</sub_title>
                <counts group_id="E1" events="21" subjects_affected="21" subjects_at_risk="634"/>
                <counts group_id="E2" events="32" subjects_affected="32" subjects_at_risk="632"/>
                <counts group_id="E3" events="9" subjects_affected="9" subjects_at_risk="319"/>
                <counts group_id="E4" events="28" subjects_affected="28" subjects_at_risk="319"/>
                <counts group_id="E5" events="17" subjects_affected="17" subjects_at_risk="185"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Myalgia</sub_title>
                <counts group_id="E1" events="86" subjects_affected="86" subjects_at_risk="634"/>
                <counts group_id="E2" events="106" subjects_affected="106" subjects_at_risk="632"/>
                <counts group_id="E3" events="46" subjects_affected="46" subjects_at_risk="319"/>
                <counts group_id="E4" events="79" subjects_affected="79" subjects_at_risk="319"/>
                <counts group_id="E5" events="68" subjects_affected="68" subjects_at_risk="185"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Headache</sub_title>
                <counts group_id="E1" events="103" subjects_affected="103" subjects_at_risk="634"/>
                <counts group_id="E2" events="89" subjects_affected="89" subjects_at_risk="632"/>
                <counts group_id="E3" events="41" subjects_affected="41" subjects_at_risk="319"/>
                <counts group_id="E4" events="59" subjects_affected="59" subjects_at_risk="319"/>
                <counts group_id="E5" events="61" subjects_affected="61" subjects_at_risk="185"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>Sponsor must have the opportunity to review at least 60 days prior to submission for publication or presentation. If review indicates that potentially patentable subject matter would be disclosed, publication or public disclosure may be delayed for a maximum of an additional 60 days to allow for filing the necessary patent applications.</restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Medical Director</name_or_title>
      <organization>Sanofi Pasteur Inc.</organization>
      <email>RegistryContactUs@sanofipasteur.com</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

